Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely align with the FDA-labeled indications, dosing concepts, administration, warnings/precautions, adverse reactions, and storage details for Norditropin. Notable gaps include an unsupported CKD-related growth failure indication, country-specific access language which is not in FDA labeling, and pregnancy-related language that requires cautious interpretation. Overall alignment is solid with targeted areas needing refinement.
Category Scores
Accurate Statements
Endikasyonlar: Büyüme hormonu eksikliği tanısı konmuş çocuklar ve yetişkinler için tedavi edilebilir.
Indications and Usage (1.1, 1.2)
Endikasyonlar: Turner sendromu için kullanılabilir.
Indications and Usage (1.1)
Endikasyonlar: Prader-Willi sendromu için kullanılabilir.
Indications and Usage (1.1)
Endikasyonlar: Doğum sonrası büyüme geriliği/SGA için kullanılabilir.
Indications and Usage (1.1); Pediatric Dosage (2.2)
Uygulama: Subkütan enjeksiyonla uygulanır.
Administration and Use Instructions (2.1)
Dozlar: Dozlar yaşa, hastalığın nedeni ve yanıtına göre doktor tarafından ayarlanır.
Administration and Use Instructions (2.1); Pediatric Dosage (2.2); Adult Dosage (2.3)
Unsupported Statements
Endikasyonlar: Kronik böbrek yetmezliğiyle ilişkili büyüme geriliği için kullanılabilir.
CKD-related growth failure is not listed among the approved indications in the provided prescribing information.
Endikasyonlar: Ülkeden ülkeye spesifik endikasyonlar değişebilir.
Does not appear as a labeled indication in the FDA-provided labeling.
Kullanım sırasında mevcut hastalıklar ve tedaviler doktor tarafından izlenmelidir.
This is a general instruction present in the label, but the formulation in the claim is broad enough to be considered non-specific; however, the labeling does include monitoring and supervision.
Erişim ve Güncellik: Novo Nordisk’in resmi Türkiye sitesi veya Türkiye’deki yetkili eczanelerden edinilir.
Access/source statements for a country-specific site are not part of FDA labeling.
Erişim ve Güncellik: Türkiye İlaç ve Tıbbi Cihaz Kurumu (TİTCK) veri tabanında da bulunabilir.
Regulatory database listings for Turkey are outside FDA labeling.
Contradictions
Important Omissions
Boxed warnings: No explicit boxed warning section identified in the provided label content; if present in the full label, it should be cited. Clarify whether any boxed warnings exist.
Importance:
High
Monitoring recommendations for IGF-1 and glucose monitoring, tumor surveillance, and other safety monitoring (nevi, intracranial hypertension follow-up) could be explicitly itemized as monitoring guidance beyond general statements.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Label documents risks such as glucose intolerance, intracranial hypertension, pancreatitis, neoplasia risk, and adverse events; overall risk is manageable with monitoring and appropriate indications. No high-severity undisclosed risks identified in the evaluated claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
CKD-related indication and country-specific access details are not part of FDA label; pregnancy language requires careful alignment with actual 8.1 content.
Suggested Improvement
Remove non-FDA-label indications (CKD-related growth failure, country-specific access statements). Align pregnancy content with on-label FDA wording. If country-specific guidance is needed, clearly label as off-label and country-specific, not on-label FDA content. Include explicit boxed warnings and robust monitoring recommendations if present in the full label, and reference them precisely.